Preeclampsia is a multisystem disorder, pathophysiology of which is still not clear. It is one
of the leading causes of maternal and fetal morbidity and mortality. Epigenetic programing is altered
during fetal life and postnatal period and after birth, this sceniaro is changed to metabolic disorders of
metabolic syndrome complex and this may contribute to future risk of hypertension, DM2, and cardiovascular
disease. During (normal and abnormal) gestations, complex physiological changes occur in
maternal blood. For studying next generation diagnostic biomarkers for maternal-fetal interface, it is
essential to explore the protein changes in maternal serum during healthy gestation. Umbilical cord blood (UCB) is in
contact with all the fetal tissues and can reflect both normal physiological as well as pathological states of the fetus. UCB
can be compared with adult blood and the diagnostic potential of UCB still remains to be tapped. UCB will be a potential
diagnostic medium in future in assessing infant health. Also, UCB can aid in detection and identification of candidate
biomarkers for various disease pathways and it can be of help in assessing the existing or future adverse effects. Patents
are available for biomarkers in preeclampsia and fewer patents are reported in UCB. Future studies will further uncover
the diagnostic value of the umbilical cord blood in human physiology and pathology.
Keywords: Cord blood, diagnostic, markers preeclampsia, maternal, patents.
Rights & PermissionsPrintExport